Literature DB >> 28836862

Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey.

Ahmed M Soliman1, Mary Kay Margolis2, Jane Castelli-Haley1, Mahesh J Fuldeore1, Charlotte D Owens1, Karin S Coyne2.   

Abstract

BACKGROUND: Uterine fibroids (UF) are associated with significant health-related quality of life (HRQL) impact. This study examined the impact of UF symptoms on HRQL.
METHODS: An online cross-sectional survey of 18 to 49 year old US women was conducted and collected demographics, UF prevalence, symptoms, and HRQL using the UFS-QOL. Descriptive statistics were used to examine the impact of symptom presence, severity, bothersomeness, and number of UF symptoms on HRQL. Analyses were weighted to match the US female population distribution. Multivariate regressions were performed with each subscale as a dependent variable to examine the impact of individual UF symptoms on HRQL.
RESULTS: A total of 59,411 (15.5%) panel members completed the prevalence screener; 4848 met inclusion criteria; 955 had UF and no hysterectomy. Mean age was 40.3; 58% were white; 63% were married/civil union. Common UF symptoms were: lower back pain (65%), fatigue/weariness (63%), bloating (61%), pelvic pain/cramping during menses (63%), and heavy bleeding during menses (54%). Mean UFS-QoL subscale scores were significantly (p < .05) worse among women with a UF symptom versus women without the symptom. Women who rated their UF symptoms as severe had significantly (p < .001) worse UFS-QoL scores than women with mild or moderate symptoms. UFS-QoL subscale scores worsened as the number of symptoms increased. In the regressions, the presence of bleeding and non-bleeding symptoms were related to worse UFS-QoL subscale scores.
CONCLUSION: HRQL among women with UF was significantly impacted by UF-related symptoms. Greater impact was observed as the number and severity of symptoms increased.

Entities:  

Keywords:  Health-related quality of life; UFS-QoL; impact; symptoms; uterine fibroids

Mesh:

Year:  2017        PMID: 28836862     DOI: 10.1080/03007995.2017.1372107

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  15 in total

1.  An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.

Authors:  Sarah Kang; Allen Brinker; S Christopher Jones; Lara Dimick-Santos; Mark I Avigan
Journal:  Drug Saf       Date:  2020-12       Impact factor: 5.606

2.  A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality.

Authors:  Ioannis Panagopoulos; Kristin Andersen; Ludmila Gorunova; Ben Davidson; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

3.  Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

Authors:  Ayman Al-Hendy; Andrea S Lukes; Alfred N Poindexter; Roberta Venturella; Claudio Villarroel; Hilary O D Critchley; Yulan Li; Laura McKain; Juan C Arjona Ferreira; Andria G M Langenberg; Rachel B Wagman; Elizabeth A Stewart
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

Review 4.  Role of Transforming Growth Factor β in Uterine Fibroid Biology.

Authors:  Michał Ciebiera; Marta Włodarczyk; Małgorzata Wrzosek; Błażej Męczekalski; Grażyna Nowicka; Krzysztof Łukaszuk; Magdalena Ciebiera; Aneta Słabuszewska-Jóźwiak; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2017-11-17       Impact factor: 5.923

Review 5.  The Role of Tumor Necrosis Factor α in the Biology of Uterine Fibroids and the Related Symptoms.

Authors:  Michał Ciebiera; Marta Włodarczyk; Magdalena Zgliczyńska; Krzysztof Łukaszuk; Błażej Męczekalski; Christopher Kobierzycki; Tomasz Łoziński; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

6.  Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.

Authors:  Andrea S Lukes; David Soper; Amanda Harrington; Vilma Sniukiene; Yifan Mo; Patrick Gillard; Lee Shulman
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

7.  Anxiety, Depression, and Quality of Life After Procedural Intervention for Uterine Fibroids.

Authors:  Kedra Wallace; Elizabeth A Stewart; Lauren A Wise; Wanda Kay Nicholson; John Preston Parry; Shuaiqi Zhang; Shannon Laughlin-Tommaso; Vanessa Jacoby; Raymond M Anchan; Michael P Diamond; Sateria Venable; Amber Shiflett; Ganesa R Wegienka; George Larry Maxwell; Daniel Wojdyla; Evan R Myers; Erica Marsh
Journal:  J Womens Health (Larchmt)       Date:  2021-06-08       Impact factor: 2.681

Review 8.  Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review.

Authors:  Michał Ciebiera; Krzysztof Łukaszuk; Błażej Męczekalski; Magdalena Ciebiera; Cezary Wojtyła; Aneta Słabuszewska-Jóźwiak; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2017-12-01       Impact factor: 5.923

9.  Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.

Authors:  James A Simon; Ayman Al-Hendy; David F Archer; Kurt T Barnhart; Linda D Bradley; Bruce R Carr; Thomas Dayspring; Eve C Feinberg; Veronica Gillispie; Sandra Hurtado; JinHee Kim; Ran Liu; Charlotte D Owens; Ozgul Muneyyirci-Delale; Alice Wang; Nelson B Watts; William D Schlaff
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

Review 10.  Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts.

Authors:  Michał Ciebiera; Marta Włodarczyk; Magdalena Ciebiera; Kornelia Zaręba; Krzysztof Łukaszuk; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2018-07-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.